| Literature DB >> 32075287 |
Diego Fernández-Lázaro1, Juan Mielgo-Ayuso2, Jesús Seco Calvo3, Alfredo Córdova Martínez2, Alberto Caballero García4, Cesar I Fernandez-Lazaro1,5.
Abstract
Physical activity, particularly high-intensity eccentric muscle contractions, produces exercise-induced muscle damage (EIMD). The breakdown of muscle fibers and the consequent inflammatory responses derived from EIMD affect exercise performance. Curcumin, a natural polyphenol extracted from turmeric, has been shown to have mainly antioxidant and also anti-inflammatory properties. This effect of curcumin could improve EIMD and exercise performance. The main objective of this systematic review was to critically evaluate the effectiveness of curcumin supplementation on EIMD and inflammatory and oxidative markers in a physically active population. A structured search was carried out following Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines in the databases SCOPUS, Web of Science (WOS), and Medline (PubMed) from inception to October 2019. The search included original articles with randomized controlled crossover or parallel design in which the intake of curcumin administered before and/or after exercise was compared with an identical placebo situation. No filters were applied to the type of physical exercise performed, the sex or the age of the participants. Of the 301 articles identified in the search, 11 met the established criteria and were included in this systematic review. The methodological quality of the studies was assessed using the McMaster Critical Review Form. The use of curcumin reduces the subjective perception of the intensity of muscle pain; reduces muscle damage through the decrease of creatine kinase (CK); increases muscle performance; has an anti-inflammatory effect by modulating the pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-8; and may have a slight antioxidant effect. In summary, the administration of curcumin at a dose between 150-1500 mg/day before and during exercise, and up until 72 h' post-exercise, improved performance by reducing EIMD and modulating the inflammation caused by physical activity. In addition, humans appear to be able to tolerate high doses of curcumin without significant side-effects.Entities:
Keywords: anti-inflammatory; antioxidants; curcumin; muscle-damaging exercise; natural polyphenols; physical activity
Mesh:
Substances:
Year: 2020 PMID: 32075287 PMCID: PMC7071279 DOI: 10.3390/nu12020501
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Methodological quality of the studies included in the systematic review.
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | |
|
| 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | |
|
| 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 7 | |
|
| 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 6 | |
|
| 13 | 14 | 12 | 14 | 14 | 13 | 12 | 15 | 14 | 15 | 14 | ||
|
| 81.3 | 87.5 | 75 | 87.5 | 87.5 | 81.3 | 75 | 93.8 | 87.5 | 93.8 | 87.5 | ||
|
| VG | VG | G | VG | VG | VG | G | E | VG | E | VG | ||
(TS) Total items fulfilled by study. (1) Criterion met; (0) Criterion not met. (TI): Total items fulfilled by items. Methodological Quality (MQ): poor (P) ≤8 points; acceptable (A) 9–10 points; good (G) 11–12 points; very good (VG) 13–14 points; excellent (E) ≥15 points.
Figure 1Selection of Studies.
Characteristics of participants and interventions in the studies included in the review.
|
| Elite Athletes | 1 Study [ |
| Moderately Active | 5 Studies [ | |
| No Regular Training before the Study | 5 Studies [ | |
|
| Commercially available curcumin supplement | 10 studies [ |
| Curcumin capsule made for the study | 1 study [ | |
|
| 150 mg/day | 1 study [ |
| 180 mg/day (2 doses of 90 mg/day) | 2 studies [ | |
| 300 mg /day (2 doses of 150 mg/day) | 1 study [ | |
| 400 mg/day | 1 study [ | |
| 400 mg /day (2 doses of 200 mg/day) | 1 study [ | |
| 500 mg / day | 1 study [ | |
| 5 g/day (2 doses of 2.5 g/day) | 1 study [ | |
| 6 g of curcumin + 60 mg of piperine/day (3 doses of 2 g of curcumin + 20 mg of piperine/day) | 1 study [ | |
| 600 mg/day (3 doses of 200 mg of curcumin) | 1 study [ | |
| 1500 mg/day (3 doses of 500 mg of curcumin) | 1 study [ | |
|
| Before Exercise | 1 study [ |
| Before and After Exercise | 9 studies [ | |
| After Exercise | 1 study [ | |
|
| 1 day | 2 studies [ |
| 4 days | 3 studies [ | |
| 6 days | 2 studies [ | |
| 7 days | 2 studies [ | |
| 56 days | 1 study [ | |
| 28 days | 1 study [ |
Summary of studies included in this systematic review.
|
| |||||
|
|
|
|
|
|
|
| Drobnic et al., 2014 [ | Randomized controlled trial single-blind | 20 moderately active men (38.1 ± 11.1 years and 32.7 ± 12.3 years) | 200 mg curcumin capsules (Phytosome Meriva) twice a day 48 h before exercise and for 24 h after | Evidence of muscle injury by MRI | ↓ RT and LT posterior and medial |
| CRP, hsCRP, ERS, MCP-1, FRAP, CAT, GPx, CK | † CRP, hsCRP, ERS, MCP-1, FRAP, CAT, GPx, CK | ||||
| IL-8 | ↓ IL-8 | ||||
| Intensity of pain | † Intensity of pain | ||||
| Sciberras et al., 2015 [ | Double-blind randomized cross-over. Subjects performed three trials in total (supplement/placebo and control) | 11 male recreational athletes (35.5 ± 5.7 years) | 500 mg of curcumin in capsules (Meriva Curcumin) 72 h before and immediately before exercise | RPE | † RPE |
| Cortisol, PCR, Hto, Hb, | † Cortisol, PCR, Hto, Hb, | ||||
| WBC, Neutrophils, IL-6, | WBC, Neutrophils, IL-6, | ||||
| IL1-RA, IL-10 | IL1-RA, IL-10 | ||||
| Questionnaire DALDA | ↑ “better than usual” | ||||
| Nicol et al., 2015 [ | Double-blind crossover randomized controlled trial | 17 moderately active men (33.8 ± 5.4 years) | 2.5 g of curcumin in capsules, 48 h before the exercise and for 72 h after | Muscle pain—VAS | ↓ Muscle pain: squatting jump (1.5−1.1; ± 1.2); Stretch butt (−1.0a-1.9; ± 0.9); Sitting on one leg (−1.4a−1.7; 90% CL ± 1.0) |
| Jump height to one leg | ↑ Jump 1 leg (15%; 90% CL ± 1 2%) | ||||
| CK | ↓ CK 24 and 48 h before (−22%; 90% CL ± 22%), (−29%; ± 21%) | ||||
| IL-6 | ↑ IL-6 at 0-h (31%; ± 29%) and 48 h (32%; ± 29%) ↓ 24 h post-exercise (−20%; ± 18%) | ||||
| TNF-α | † TNF-α | ||||
| Tanabe et al., 2015 [ | Single-blind crossover randomized controlled trial | 14 young men without regular resistance training (23.5 ± 2.3 years) | 150 mg curcumin capsules (Theracurcumin Theravalues) twice a day 1 h before exercise and 12 h later | MVC Torque | ↓ MVC Torque |
| ROM | † ROM | ||||
| Upper arm circumference | † Upper arm circumference | ||||
| Muscle pain—VAS | †VAS | ||||
| CK | ↓ CK (maximum activity) | ||||
| IL-6 | † IL-6 | ||||
| TNF-α | † TNF-α | ||||
|
| |||||
|
|
|
|
|
|
|
| McFarlin et al., 2016 [ | Randomized controlled trial double blind | 28 men and women without regular resistance training | 400mg curcumin capsules (Long-life) | Subjective quadriceps pain | † Subjective quadriceps pain |
| ADL | †ADL | ||||
| CK | ↓CK | ||||
| TNF-α | ↓TNF-α | ||||
| IL-6 | †IL-6 | ||||
| IL-8 | ↓IL-8 | ||||
| IL-10 | †IL-10 | ||||
| Nakhostin-Roohi et al., 2016 [ | Controlled test randomized crossed double-blind | 10 young men without regular training with weights (25.0 ± 1.6 years) | 150 mg of curcumin gin capsules (Theravalues) Immediately after exercise | Muscle pain—VAS | ↓ VAS 48–72 h |
| TAC | ↑ TAC | ||||
| CK | ↓ CK | ||||
| ALT | ↓ ALT | ||||
| AST | ↓ AST | ||||
| Delecroix et al., 2017 [ | A randomized, balanced cross-over | 10 rugby players elite level (20.7 ± 1.4 years) | 2 g curcumin + 20 mg of piperine in capsules (MGD Nature) 3 times/day48h before exercise and for 48 h after exercise | 6-s power sprint | < Group reduction EXP: (−1.77 ± 7.25%; 1277 ± 153 W). CON Group (−13.6 ± 13.0%; 1130 ± 241 W) |
| CMJ | ↑ CMJ (ES = −0.56; CI 90% = 0.81−0.32) | ||||
| CK | † CK 24, 48, 72 h post-exercise | ||||
| Muscle pain—Hooper scale | † Muscle pain—Hooper scale | ||||
| Subjective quadriceps pain | † Subjective quadriceps pain | ||||
| Tanabe et al., 2018 [ | Double-blind crossover randomized controlled trial | Exp1: 10 men (28.5 ± 3.4 years) Exp2: 10 men (29.0 ± 3.9 years) Both untrained 3-7 days prior to assay | 90mg curcumin capsules (Theracurcumin Theravalues) 2 times/day Exp1: 7 days before exercise Exp2: 7 days after exercise | MVC Torque | Exp1:† Exp2:↑ MVC Torque |
| ROM | Exp1:† Exp2:↑ ROM | ||||
| Muscle pain -VAS | Exp1:† Exp2: ↓ VAS | ||||
| T2 | Exp1:† Exp2: † T2 | ||||
| CK | Exp1:† Exp2:↓ CK | ||||
| TNF- α | Exp1:† Exp2: † TNF- α | ||||
| IL-8 | Exp1: ↓ Exp2: † IL-8 | ||||
| d-ROMs | Exp1:† Exp2: † d-ROMs | ||||
| BAP | Exp1:† Exp2: † BAP | ||||
| Tanabe et al., 2019 [ | Single-Blind Parallel Randomized Trial | 24 young men without intense training during the study period PRE (28.8 ± 3.6 years) POST (29.8 ± 3.4 years) CON (28.0 ± 3.2 years) | 90 mg curcumin capsules (Theracurcumin Theravalues) twice a day PRE: 7 days before exercise POST: 4 days after exercise CON: 4 days after exercise | MVC Torque | PRE: † POST: † MVC Torque |
| ROM | PRE: † POST: ↑ ROM | ||||
| Muscle pain—VAS | PRE: † POST: ↓ VAS | ||||
| CK | PRE: † POST: † CK | ||||
|
| |||||
|
|
|
|
|
|
|
| Jäger et al., 2019 [ | Randomized controlled trial double-blind | 63 men (31) and women (32) (21 ± 2 years) physically active meeting ACSM guidelines | G1: Placebo (PLB) G2: 50 mg curcumin in capsules (CurcuWIN®)G3: 200 mg curcumin in capsules (CurcuWIN®)3 times/day (breakfast/lunch/dinner) | Subjective muscle pain anterior, posterior, and total scale 100 mm Maximum extension torque and isokinetic flexion Extension power and isokinetic flexion Isometric torque Measurements: 1 h, 24 h, 48 h, and 72 h post-exercise | ↑ Subjective muscle pain (anterior, posterior) G 1, 2, and 3 † Subjective (total) muscle pain G3 1 h and 24 h post-exercise † Maximum bending torque G2 † Bending power G2 |
| Basham et al., 2019 [ | Randomized controlled trial double-blind | 20 men elite level (21.7 ± 2.9 years) physically active compliance with ACSM guidelines | 1.5 g curcumin/69 mg curcuminoids 500 mg capsule (CurcuFresh, NOW FoodsUSA) twice a day (2 breakfast/1 dinner) | Oxidative stress | ↓ CK ( |
(A) ↑: Statistically significant increase; †: change without statistical significance; ↓: Statistically significant decrease; MRI: magnetic resonance imaging; RT: right thigh; LT: left thigh; CRP: C-reactive protein; hsCRP: high sensitivity CRP; ERS: erythrocyte sedimentation; MCP-1: monocyte 1 chemotherapeutic protein; FRAP: Ferric reduction capacity of plasma; CAT: catalase; GPx: glutathione peroxidase; CK: creatine kinase; IL-8: interleukin 8; RPE: subjective perception of effort; Hto: hematocrit; Hb: hemoglobin; WBC: white blood cell count; IL-6: interleukin 6; IL1-RA: interleukin 1-RA; IL-10: interleukin 10; DALDA: daily analysis of life demands in athletes; VAS: visual analog scale; TNF-α: tumor necrosis factor alpha; CVS: maximum voluntary contraction; ROM: range of motion; TAC: Total Antioxidant Capacity; ALT: alanine aminotransferase; AST: aspartate aminotransferase. (B) ADL: Activities of daily living; CMJ: Contra movement jump; MVC Torque: Maximum voluntary contraction torque; ROM: Range of motion; T2: Transverse relaxation time; d-ROMs: Derivatives of reactive oxygen metabolites; BAP: Biological antioxidant potential; EXP: Experimental; CON: Control. (C) &: Unchanged; PLB: Placebo; G: Group; MDA: Malondialdehyde; ACSM: The American College of Sports Medicine.